[Skip to Navigation]
Sign In
Comment & Response
May 9, 2019

Guidelines for Secondary Solid Cancers Among HSCT Recipients

Author Affiliations
  • 1Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Azienda Ospedaliera Universitaria, Università degli Studi della Campania “Luigi Vanvitelli,” Naples, Italy
  • 2Department of Internal and Specialty Medicine, Azienda Ospedaliera Universitaria, Università degli Studi della Campania “Luigi Vanvitelli,” Naples, Italy
JAMA Oncol. 2019;5(7):1064. doi:10.1001/jamaoncol.2019.0617

To the Editor We read with interest the cohort study conducted by Tichelli and colleagues1 of patients who developed a second solid cancer (SSC) after a transplant. Hematopoietic stem cell transplant (HSCT) recipients have a considerable risk of developing secondary solid cancers 5 years or more after HSCT owing to factors such as myeloablative total-body irradiation, young age at HSCT, chronic graft-vs-host disease, and prolonged immunosuppressive treatment longer than 24 months.2,3 Therefore, Inamoto et al4 proposed guidelines to help clinicians provide screening and preventive care for secondary cancers among HSCT recipients.

Add or change institution
×